These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 7587045

  • 1. Cefotaxime and ceftriaxone use evaluation in pediatrics. Considerations of cost effectiveness.
    Lee CK, Glenn DJ.
    Diagn Microbiol Infect Dis; 1995; 22(1-2):231-3. PubMed ID: 7587045
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic exchange of cefotaxime for ceftriaxone: evaluation, implementation, and subsequent cost savings at a 300-bed community hospital.
    Rawlings RD.
    Diagn Microbiol Infect Dis; 1995; 22(1-2):235-7. PubMed ID: 7587046
    [Abstract] [Full Text] [Related]

  • 3. [Cost-effectiveness comparative study of ceftriaxone verus cefotaxime in the treatment of complicated urinary infections].
    Martínez Jabaloyas JM, Sanz Chinesta S, Jiménez Cruz JF, Flores Corral N, Unda Urzaiz M, Leiva Galvis O, González Romojaro V, Hernández Fernández C, Lledó García E, Rioja Sanz LA, Gonzalvo Ibarra A, Camacho González JE, Ruíz Alvárez-Cienfuegos F, Resel Estévez L, Corral Saleta J, Burgos Rodríguez R, Del Rosal Samaniego JM.
    Actas Urol Esp; 1997; 21(7):668-74. PubMed ID: 9412209
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients.
    Parrish AG.
    S Afr Med J; 1998 Sep; 88(9):1046, 1048; author reply 1050-1. PubMed ID: 9798485
    [No Abstract] [Full Text] [Related]

  • 6. Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections.
    Plosker GL, Foster RH, Benfield P.
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):91-106. PubMed ID: 10175990
    [Abstract] [Full Text] [Related]

  • 7. A cost-effectiveness evaluation of 3 antimicrobial regimens for the prevention of infective complications after abdominal surgery.
    Anderson G, Boldiston C, Woods S, O'Brien P.
    Arch Surg; 1996 Jul; 131(7):744-8. PubMed ID: 8678775
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness decision analysis of intramuscular ceftriaxone versus oral cefixime in adolescents with gonococcal cervicitis.
    Friedland LR, Kulick RM, Biro FM, Patterson A.
    Ann Emerg Med; 1996 Mar; 27(3):299-304. PubMed ID: 8599487
    [Abstract] [Full Text] [Related]

  • 11. A retrospective analysis of twice-daily cefotaxime compared to conventional therapy for the treatment of infections in a USA hospital.
    Burke JP, Pestotnik SL, Classen DC, Lloyd JF.
    Diagn Microbiol Infect Dis; 1995 Mar; 22(1-2):167-9. PubMed ID: 7587034
    [Abstract] [Full Text] [Related]

  • 12. Cost comparison of single daily i.v. doses of ceftriaxone versus continuous infusion of cefotaxime.
    Hitt CM, Nightingale CH, Quintiliani R, Nicolau DP.
    Am J Health Syst Pharm; 1997 Jul 15; 54(14):1614-8. PubMed ID: 9248605
    [Abstract] [Full Text] [Related]

  • 13. A team approach to hospital formulary replacement.
    Lee J, Carlson JA, Chamberlain MA.
    Diagn Microbiol Infect Dis; 1995 Jul 15; 22(1-2):239-42. PubMed ID: 7587047
    [Abstract] [Full Text] [Related]

  • 14. Selection of cephalosporins for hospital formularies.
    Wilson WR.
    Diagn Microbiol Infect Dis; 1995 Jul 15; 22(1-2):129-34. PubMed ID: 7587026
    [Abstract] [Full Text] [Related]

  • 15. Pharmacoeconomic considerations in the ambulatory use of parenteral cephalosporins.
    Tice AD.
    Drugs; 2000 Jul 15; 59 Suppl 3():29-35; discussion 47-9. PubMed ID: 10845411
    [Abstract] [Full Text] [Related]

  • 16. Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime.
    Adu A, Armour CL.
    Drugs; 1995 Sep 15; 50(3):423-39. PubMed ID: 8521766
    [Abstract] [Full Text] [Related]

  • 17. Outcome of a ceftriaxone/cefotaxime interchange programme in a major teaching hospital.
    Gutensohn A, Bunz D, Frighetto L, Jewesson P.
    Chemotherapy; 1991 Sep 15; 37 Suppl 3():15-21. PubMed ID: 1909228
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the efficacy, safety and cost of cefixime, ceftriaxone and aztreonam in the treatment of multidrug-resistant Salmonella typhi septicemia in children.
    Girgis NI, Sultan Y, Hammad O, Farid Z.
    Pediatr Infect Dis J; 1995 Jul 15; 14(7):603-5. PubMed ID: 7567290
    [Abstract] [Full Text] [Related]

  • 19. Using cost of infection as a tool to demonstrate a difference in prophylactic antibiotic efficacy: a prospective randomized comparison of the pharmacoeconomic effectiveness of ceftriaxone and cefotaxime prophylaxis in abdominal surgery.
    Woodfield JC, Van Rij AM, Pettigrew RA, van der Linden A, Bolt D.
    World J Surg; 2005 Jan 15; 29(1):18-24. PubMed ID: 15599747
    [Abstract] [Full Text] [Related]

  • 20. Ceftriaxone is twice as cost-effective as standard therapy in biliary tract infection.
    Zoepf T, Jakobs R, Riemann JF.
    Hepatogastroenterology; 2004 Jan 15; 51(58):941-5. PubMed ID: 15239219
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.